Generic Name and Formulations:
Memantine HCl extended-release, donepezil HCl; 7mg/10mg, 14mg/10mg, 21mg/10mg, 28mg/10mg; caps.
Indications for NAMZARIC:
Moderate-to-severe dementia of the Alzheimer's type in patients stabilized on 10mg of donepezil HCl once daily.
Swallow whole or may open caps and sprinkle on applesauce, then consume entire contents; do not divide doses. Patients stabilized on donepezil HCl 10mg: initially 7mg/10mg once daily in the PM; increase at minimum weekly intervals in 7mg increments of memantine HCl to max maintenance dose of 28mg/10mg once daily; severe renal impairment (CrCl 5–29mL/min): initially 7mg/10mg once daily in the PM; increase to maintenance dose of 14mg/10mg once daily after one week. Patients stabilized on both components: 28mg/10mg once daily in the PM. Start the day after last dose of memantine HCl and donepezil HCl given separately. Severe renal impairment (CrCl 5–29mL/min): 14mg/10mg once daily.
Cardiac conduction abnormalities. Peptic ulcer. Monitor for GI bleeding. GU obstruction. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine levels. Seizures. Asthma or COPD. Severe hepatic impairment. Pregnancy. Nursing mothers.
NMDA receptor antagonist + acetylcholinesterase inhibitor.
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). Memantine plasma levels may be increased by urinary alkalinizers. Donepezil potentiated by CYP3A4 (eg, ketoconazole) and CYP2D6 (eg, quinidine) inhibitors. CYP3A4 inducers (eg, phenytoin, carbamazepine, dexamethasone, rifampin, phenobarbital) may increase the rate of elimination of donepezil. Antagonizes anticholinergics. Additive effects with succinylcholine-type muscle relaxants (during anesthesia), other cholinesterase inhibitors, cholinergic agonists (eg, bethanechol). Concomitant NSAIDs may increase risk of GI bleed.
Headache, diarrhea, dizziness, anorexia, vomiting, nausea, ecchymosis.
Caps 7mg/10mg, 21mg/10mg—30; 14mg/10mg, 28mg/10mg—30, 90
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer